Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription

[1]  F. Prósper,et al.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia , 2011, Haematologica.

[2]  M. Kurokawa,et al.  Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. , 2011, Blood.

[3]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Tanay,et al.  Dynamic combinatorial interactions of RUNX1 and cooperating partners regulates megakaryocytic differentiation in cell line models. , 2011, Blood.

[5]  A. Bert,et al.  Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1. , 2010, Leukemia research.

[6]  K. Döhner,et al.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Luleci,et al.  Array comparative genomic hybridization analysis of adult acute leukemia patients. , 2010, Cancer genetics and cytogenetics.

[8]  C. Cucarella,et al.  Characterization of the Human Insulin-induced Gene 2 (INSIG2) Promoter , 2010, The Journal of Biological Chemistry.

[9]  Henriette O'Geen,et al.  Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. , 2009, Molecular cell.

[10]  R. Wieser,et al.  Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response , 2009, The FEBS journal.

[11]  A. Goldfarb.  Megakaryocytic programming by a transcriptional regulatory loop: A circle connecting RUNX1, GATA‐1, and P‐TEFb , 2009, Journal of cellular biochemistry.

[12]  G. Nucifora,et al.  EVI1 Impairs myelopoiesis by deregulation of PU.1 function. , 2009, Cancer research.

[13]  S. Ogawa,et al.  Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. , 2008, Cell stem cell.

[14]  B. Löwenberg,et al.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. , 2008, Blood.

[15]  R. Wieser,et al.  Expression and prognostic significance of different mRNA 5′‐end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration , 2008, Genes, chromosomes & cancer.

[16]  R. Wieser.  The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. , 2007, Gene.

[17]  G. Nucifora,et al.  Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. , 2007, Cancer research.

[18]  J. Biggs,et al.  AML1/RUNX1 Phosphorylation by Cyclin-Dependent Kinases Regulates the Degradation of AML1/RUNX1 by the Anaphase-Promoting Complex , 2006, Molecular and Cellular Biology.

[19]  G. Nucifora,et al.  Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow Cells , 2006, Molecular and Cellular Biology.

[20]  F. Mikhail,et al.  Normal and transforming functions of RUNX1: A perspective , 2006, Journal of cellular physiology.

[21]  G. Nucifora,et al.  EVI1 and hematopoietic disorders: history and perspectives. , 2006, Gene.

[22]  R. Wieser,et al.  Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends. , 2005, Gene.

[23]  A. Iwama,et al.  Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA‐2 expression , 2005, The EMBO journal.

[24]  Motomi Osato.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia , 2004, Oncogene.

[25]  J. Bravo,et al.  Mutagenesis of the Runt Domain Defines Two Energetic Hot Spots for Heterodimerization with the Core Binding Factor β Subunit* , 2003, Journal of Biological Chemistry.

[26]  S. Rollinson,et al.  Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7 , 2002, Genes, chromosomes & cancer.

[27]  J. Yokota,et al.  EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. , 2002, Biochemical and biophysical research communications.

[28]  J. de Gunzburg,et al.  Thrombopoietin-Mediated Sustained Activation of Extracellular Signal-Regulated Kinase in UT7-Mpl Cells Requires Both Ras–Raf-1- and Rap1–B-Raf-Dependent Pathways , 2001, Molecular and Cellular Biology.

[29]  R. Muise-Helmericks,et al.  Signal transduction and the Ets family of transcription factors , 2000, Oncogene.

[30]  T. Toki,et al.  Expression of transcription factors during megakaryocytic differentiation of CD34+ cells from human cord blood induced by thrombopoietin. , 2000, The Tohoku journal of experimental medicine.

[31]  R. Treisman,et al.  ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry , 1999, Oncogene.

[32]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[33]  A. Goldfarb,et al.  Article Title: RUNX1 and GATA -1 Coexpression and Cooperation in Megakaryocytic Differentiation , 2003 .

[34]  B. Wasylyk,et al.  The Ets family of transcription factors. , 1993, European journal of biochemistry.